| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 02/22/2001 | WO2001012233A2 Sustained release formulation of a peptide |
| 02/22/2001 | WO2001012222A1 Immunological tolerance-induction agent |
| 02/22/2001 | WO2001012202A2 Use of chemical chelators as reversal agents for drug-induced neuromuscular block |
| 02/22/2001 | WO2001012197A1 Pyridomorphinans, thienomoprhinans and use thereof |
| 02/22/2001 | WO2001012196A1 Pyridomorphinans and use thereof |
| 02/22/2001 | WO2001012195A2 Use of morphine derivatives as medicaments for the treatment of neuropathic problems |
| 02/22/2001 | WO2001012189A1 3(5)-amino-pyrazole derivatives, process for their preparation and their use as antitumor agents |
| 02/22/2001 | WO2001012186A1 Cell adhesion inhibitors |
| 02/22/2001 | WO2001012185A1 Methods and compositions for bisubstrate inhibitors of acetyltransferases |
| 02/22/2001 | WO2001012184A1 Neurotherapeutic composition and method |
| 02/22/2001 | WO2001012175A1 Uses compositions for treating or preventing sleep disturbances using very low doses of cyclobenzaprine |
| 02/22/2001 | WO2001012174A1 Cyclobenzaprine for treating generalized anxiety disorder and compositions thereof |
| 02/22/2001 | WO2001012171A2 Pharmaceutical compositions comprising clavulanic acid or derivative thereof for the treatment of behavioral diseases |
| 02/22/2001 | WO2001012170A2 Compositions including modafinil for treatment of attention deficit hyperactivity disorder and multiple sclerosis fatigue |
| 02/22/2001 | WO2001012155A1 Compositions and methods for enhanced absorption of hydrophilic therapeutic agents |
| 02/22/2001 | WO2001011967A1 Novel hypoxanthine and thiohypoxanthine compounds |
| 02/22/2001 | WO2000077179A3 Human poly(adp-ribose) polymerase 2 materials and methods |
| 02/22/2001 | WO2000072863A3 Uses of h-trek-1 polypeptides and polynucleotides encoding them |
| 02/22/2001 | WO2000071538A3 1-trifluoromethyl-4-hydroxy-7-piperidinyl-aminomethylchroman derivatives |
| 02/22/2001 | WO2000071514A8 α-AMINO-β-SULFONYL HYDROXAMIC ACID COMPOUNDS |
| 02/22/2001 | WO2000055126A3 N-cyanomethylamides as protease inhibitors |
| 02/22/2001 | WO1999063996A8 Multivalent agonists, partial agonists, inverse agonists and antagonists of the 5ht2 receptors |
| 02/22/2001 | DE19939756A1 New 1-(1-ethyl-piperidin-4-yl)-1-(phenyl or heterocyclyl)-alkanol derivatives, are 5-HT(2A) receptor antagonists useful e.g. for treating schizophrenia, depression, memory disorders or eating disorders |
| 02/22/2001 | DE19938823A1 Treatment of restless leg syndrome symptoms, using synergistic combination of alpha-2 agonist, preferably clonidine, and another neuro-psychic drug, e.g. pramipexol |
| 02/22/2001 | DE19910108C2 Zellen, die ein Amyloidvorläuferprotein und eine alpha-Sekretase coexprimieren, ein Testverfahren zur Identifikation alpha-Sekretase-aktiver Substanzen sowie eines zur Identifikation weiterer Sekretasen, ein Testverfahren zur Bestimmung der Anfälligkeit gegenüber Morbus Alzheimer und Verwendung von Nukleinsäuren, die für eine alpha-Sekretase codieren, für die Gentherapie Cells, which co-express an amyloid precursor protein and an alpha-secretase, a test method for identifying alpha-secretase active substances as well as one further for identifying secretases, a test method for determining the susceptibility to Alzheimer's disease, and use of nucleic acids encoding an alpha-secretase , for gene therapy |
| 02/22/2001 | CA2698353A1 Pharmaceutical compounds |
| 02/22/2001 | CA2689735A1 Compositions comprising modafinil for treatment of fatigue associated with multiple sclerosis |
| 02/22/2001 | CA2385431A1 Tgf-beta receptor polynucleotides, polypeptides, and antibodies |
| 02/22/2001 | CA2383691A1 Human tumor necrosis factor receptor tr16 |
| 02/22/2001 | CA2383268A1 Pyrazoloanthrone and derivatives thereof as jnk inhibitors and their compositions |
| 02/22/2001 | CA2382265A1 Prostaglandin derivatives |
| 02/22/2001 | CA2382148A1 25 human secreted proteins |
| 02/22/2001 | CA2382095A1 Methods of inhibiting binding of .beta.-sheet fibril to rage and consequences thereof |
| 02/22/2001 | CA2382019A1 Isomerase proteins |
| 02/22/2001 | CA2382018A1 Retinoid receptor interacting polynucleotides, polypeptides, and antibodies |
| 02/22/2001 | CA2382015A1 Membrane associated proteins |
| 02/22/2001 | CA2381981A1 Orally active peptides that prevent cell damage and death |
| 02/22/2001 | CA2381979A1 Pgpcr-3 polypeptides and dna sequences thereof |
| 02/22/2001 | CA2381976A1 Pharmaceutical compositions containing thiazolidinedione derivatives and process for their preparation |
| 02/22/2001 | CA2381975A1 Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
| 02/22/2001 | CA2381971A1 Amines substituted with a tetrahydroquinolinyl group, an aryl or heteroaryl group and an alkyl group, having retinoid-like biological acitity |
| 02/22/2001 | CA2381700A1 Method for identifying modulating compounds of neurotransmitters |
| 02/22/2001 | CA2381551A1 Pyrimidine-2,4,6-trione metalloproteinase inhibitors |
| 02/22/2001 | CA2381409A1 Nitric ester derivatives |
| 02/22/2001 | CA2380953A1 Methods, compositions and kits for promoting recovery from damage to the central nervous system |
| 02/22/2001 | CA2380820A1 Neurotherapeutic clavulanate composition and method |
| 02/22/2001 | CA2380817A1 Cell adhesion inhibitors |
| 02/22/2001 | CA2380814A1 Pyridomorphinans, thienomorphinans and use thereof |
| 02/22/2001 | CA2380798A1 Methods and compositions for bisubstrate inhibitors of acetyltransferases |
| 02/22/2001 | CA2380642A1 Compositions and methods for enhanced absorption of hydrophilic therapeutic agents |
| 02/22/2001 | CA2380432A1 Uses compositions for treating or preventing sleep disturbances using very low doses of cyclobenzaprine |
| 02/22/2001 | CA2380373A1 Cyclobenzaprine for treating generalized anxiety disorder and compositions thereof |
| 02/22/2001 | CA2379356A1 Novel hypoxanthine and thiohypoxanthine compounds |
| 02/22/2001 | CA2378332A1 Hydroxamic acid compounds useful as matrix metalloproteinase inhibitors |
| 02/22/2001 | CA2377662A1 Novel protein phosphatases and diagnosis and treatment of phosphatase-related disorders |
| 02/22/2001 | CA2377646A1 Indole derivatives, process for their preparation, pharmaceutical compositions containing them and their medicinal application |
| 02/22/2001 | CA2377637A1 Condensed indoline derivatives and their use as 5ht, in particular 5ht2c, receptor ligands |
| 02/21/2001 | EP1077217A2 Neuroactive peptides and their use |
| 02/21/2001 | EP1076696A2 Human receptor molecules |
| 02/21/2001 | EP1076659A1 Paroxetine 10-camphorsulfonate for treatment of cns disorders |
| 02/21/2001 | EP1076658A1 Serotonergic agents |
| 02/21/2001 | EP1076650A1 Aryl fused azapolycyclic compounds |
| 02/21/2001 | EP1076647A2 Antipsychotic indolyl derivatives |
| 02/21/2001 | EP1076644A1 N-substituted aminotetralins as ligands for the neuropeptide y y5 receptor useful in the treatment of obesity and other disorders |
| 02/21/2001 | EP1076563A1 Dipeptide caspase inhibitors and the use thereof |
| 02/21/2001 | EP1076562A1 Glucocorticoid receptor antagonists for the treatment of dementia |
| 02/21/2001 | EP1076559A2 Cabergoline and pramipexole for treating cns diseases, especially parkinson's disease |
| 02/21/2001 | EP0526452B1 Hybrid immunoglobulins |
| 02/21/2001 | CN1284951A Triazine compounds for treatment of CNS disorders |
| 02/21/2001 | CN1284946A Substituted isoquinoline derivatives and their use as anticonvulsants |
| 02/21/2001 | CN1284945A Substituted pyriding and pyridazine compounds and their pharmaceutical use |
| 02/21/2001 | CN1284880A Hyperhydrated citicoline, process and use |
| 02/21/2001 | CN1284879A Method for preventing abuse of opioid dosage forms |
| 02/21/2001 | CN1284874A 5-HT1F agonists |
| 02/21/2001 | CN1284865A Pharmaceutical compositions containing micronized bicyclic drugs |
| 02/21/2001 | CN1284505A Azabicyclic compound |
| 02/21/2001 | CN1284367A Hemiplegia treating Chinese medicine |
| 02/21/2001 | CN1284366A Preparation of life prolonging preparation |
| 02/21/2001 | CN1284351A Red sage containing medicine composition and its preparation and use |
| 02/21/2001 | CN1284331A Application of 5,3',5'-trihydroxy-methoxyl dihydroflavone in preparing medicine |
| 02/21/2001 | CN1062269C Novel (R)-5-carbamyl-8-fluoro-3-N, N-disubstituted amino-3, 4-dihydro-2H-1-benzopyranes |
| 02/21/2001 | CN1062263C Semicarbazones having CNS activity and pharmaceutical preparations containing same |
| 02/21/2001 | CN1062182C Novel physiologically active substance |
| 02/20/2001 | US6191172 Used in drugs and cosmetics |
| 02/20/2001 | US6191161 Prolylendopeptidase inhibitors |
| 02/20/2001 | US6191160 Spiro-indolines as Y5 receptor antagonists |
| 02/20/2001 | US6191154 Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases |
| 02/20/2001 | US6191153 Schizophrenia, parkinson's disease |
| 02/20/2001 | US6191152 Cardiovascular disorders, nervous system disorders |
| 02/20/2001 | US6191149 Heterocyclic derivative and medicine |
| 02/20/2001 | US6191142 Aroyl aminoacyl pyrroles for use in the treatment of neuropathic pain |
| 02/20/2001 | US6191140 Potassium channel modulators; muscle relaxants; controlling cell membranes |
| 02/20/2001 | US6191139 Antidepressant |
| 02/20/2001 | US6191137 Pharmaceutical composition for oral administration |
| 02/20/2001 | US6191132 Use of quisqualate receptor antagonists |
| 02/20/2001 | US6191130 Cyclohexane derivatives difunctionalised in 1,4 as ligands of 5T H1A receptors |
| 02/20/2001 | US6191127 Antiinflammatory agents, autoimmune diseases, cardiovascular disorders, nervous system disorders |
| 02/20/2001 | US6191126 Topical administering |
| 02/20/2001 | US6190909 TH2-specific gene |
| 02/20/2001 | US6190887 Expression of an exogenous gene in a mammalian cell by use of a non-mammalian DNA virus having an altered coat protein |